Martin is seasoned entrepreneur with 32 years experience heading small technology companies. Using his broad based technology and management skills, Martin has established a network of experts in the fields of genetics and nutrition. Together with a strong manufacturing and quality control background he is poised to successfully launch a next generation nutritional formulation called LEAP. The LEAP Study he and his team designed is intended to provide evidence of the formula's efficacy, which should allow specific marketing claims to be made about the product. Martin is confident that the LEAP formula will make a dramatic impact on those who take it. The successful introduction of LEAP into the nutritional supplement market can represent a significant LEAP forward in the field of nutrition and epigenetic research.
40 years experience and knowledge of nutritional supplementation, combined with his last 15 years experience in the field of genetics are the foundation for the LEAP formula. He has a master’s degree in polymer engineering and as President & CEO of CyGene Laboratories, Inc., was a pioneer in offering genetic testing to the public. He is considered an expert in nutri-genomics and personalized medicine and his arguments against allowing gene patents were referenced and included in the recent Supreme Court case that succeeded in striking down the eligibility of gene patents. This Supreme Court ruling was made in June 2013, and he is referenced on page 16-17 of the brief filed with the court http://www.aclu.org/files/assets/2013.01.31_-_american_medical_association_et_al._amicus.pdf
Dr. Keith Zucker has served as Supervisor/Director of CLIA-certified clinical diagnostic and research laboratories for over 23 years, the last 13 years as Supervisor of both the Molecular Pathology and Microbiology divisions at Children’s Hospital Central California in Fresno, CA. He possesses two Clinical Laboratory Scientist licenses, one in Genetic Molecular Biology (CGMB) and the other in Microbiology, as well as national certification as a Specialist in Clinical Molecular Biology (CLSsp[MB]) from ASCP. Dr. Zucker maintains two adjunct faculty appointments at California State University, Fresno, and at the School of Pharmacy of California Health Sciences University.
Prior to taking his current position at Children’s Hospital, Dr. Zucker established and directed two clinical molecular testing laboratories, one in the HLA typing service and the other in Molecular Microbiology, as well as his own research lab for the Division of Transplantation at the University of Miami School of Medicine. He is an expert in the fields of Molecular Diagnostics, Clinical Microbiology, and Immunology.
While at the University of Miami, Dr. Zucker co-founded CyGene Laboratories, Inc. a biotechnology company that specializes in personalized genomic testing services using state-of-the-art genotyping methods. He was responsible for research and development of the genetic marker panels that constituted the company’s product line as well as contributed to the knowledge-based result interpretation system. He served as Chief Scientific Consultant and Director of New Product Development for the company.